How Does Solara Active Pharma Sciences's (NSE:SOLARA) P/E Compare To Its Industry, After Its Big Share Price Gain?

Solara Active Pharma Sciences (NSE:SOLARA) shareholders are no doubt pleased to see that the share price has had a great month, posting a 32% gain, recovering from prior weakness. And the full year gain of 27% isn't too shabby, either!

Assuming no other changes, a sharply higher share price makes a stock less attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that deep value investors might steer clear when expectations of a company are too high. Perhaps the simplest way to get a read on investors' expectations of a business is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

See our latest analysis for Solara Active Pharma Sciences

Does Solara Active Pharma Sciences Have A Relatively High Or Low P/E For Its Industry?

Solara Active Pharma Sciences's P/E of 10.46 indicates relatively low sentiment towards the stock. We can see in the image below that the average P/E (16.5) for companies in the pharmaceuticals industry is higher than Solara Active Pharma Sciences's P/E.

Its relatively low P/E ratio indicates that Solara Active Pharma Sciences shareholders think it will struggle to do as well as other companies in its industry classification. While current expectations are low, the stock could be undervalued if the situation is better than the market assumes. You should delve deeper. I like to check if company insiders have been buying or selling.

How Growth Rates Impact P/E Ratios

P/E ratios primarily reflect market expectations around earnings growth rates. Earnings growth means that in the future the 'E' will be higher. That means unless the share price increases, the P/E will reduce in a few years. And as that P/E ratio drops, the company will look cheap, unless its share price increases.

In the last year, Solara Active Pharma Sciences grew EPS like Taylor Swift grew her fan base back in 2010; the 150% gain was both fast and well deserved.

Don't Forget: The P/E Does Not Account For Debt or Bank Deposits

It's important to note that the P/E ratio considers the market capitalization, not the enterprise value. In other words, it does not consider any debt or cash that the company may have on the balance sheet. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

While growth expenditure doesn't always pay off, the point is that it is a good option to have; but one that the P/E ratio ignores.

So What Does Solara Active Pharma Sciences's Balance Sheet Tell Us?

Solara Active Pharma Sciences has net debt worth 15% of its market capitalization. That's enough debt to impact the P/E ratio a little; so keep it in mind if you're comparing it to companies without debt.

The Verdict On Solara Active Pharma Sciences's P/E Ratio

Solara Active Pharma Sciences has a P/E of 10.5. That's around the same as the average in the IN market, which is 10.2. Given it has reasonable debt levels, and grew earnings strongly last year, the P/E indicates the market has doubts this growth can be sustained. Since analysts are predicting growth will continue, one might expect to see a higher P/E so it may be worth looking closer. What we know for sure is that investors have become more excited about Solara Active Pharma Sciences recently, since they have pushed its P/E ratio from 7.9 to 10.5 over the last month. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is 'blood in the streets', then you may feel the opportunity has passed.

Investors have an opportunity when market expectations about a stock are wrong. People often underestimate remarkable growth -- so investors can make money when fast growth is not fully appreciated. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

You might be able to find a better buy than Solara Active Pharma Sciences. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.